Asuragen appoints BMD as exclusive distributor of Signature Oncology Products in France

Mar 22 2010

Asuragen, Inc., a leader in the development of molecular diagnostics, announced today the appointment of Biomedical Diagnostics SA (BMD), a leading medical diagnostic company in Europe, as its exclusive distributor of Signature^® Oncology Products in France. Asuragen’s Signature Oncology Portfolio comprises multiplex assays for the detection of mutations in solid and hematologic malignancies. These include a research assay for KRAS and BRAF mutations, the LTx CE marked IVD assay to detect fusion transcripts in total RNA from whole blood or bone marrow to aid in the clinical diagnosis of translocation positive leukemias, and an assay for the simultaneous detection of the most common NPM1 Mutations. All these assays utilize multiplex RT-PCR followed by multiplex detection on the Luminex^® 100 IS™ or 200™ System.

“As we expand our Signature Oncology Portfolio with the launch of our Signature KRAS/BRAF multiplex assay, we are pleased to add a strong commercial partner like BMD to our growing network of international distributors”

“As we expand our Signature Oncology Portfolio with the launch of our Signature KRAS/BRAF multiplex assay, we are pleased to add a strong commercial partner like BMD to our growing network of international distributors,” said President, Rollie Carlson. “In addition, BMD will be supporting our efforts in establishing clinical validation sites for the Signature KRAS/BRAF assay in France.”

“We are pleased by the confidence granted to us by Asuragen for the exclusive distribution of their products developed on the Luminex platform. This partnership will enable BMD to enlarge its offering of very innovative products in the field of oncology diagnostics,” said BMD’s General Manager, Denis Fortier.